Drug Shortage Report for INTEGRILIN
| Report ID | 51168 |
| Drug Identification Number | 02240352 |
| Brand name | INTEGRILIN |
| Common or Proper name | Eptifibatide Injection |
| Company Name | MERCK CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | EPTIFIBATIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | 20MG/10ML BOLUS VIAL |
| ATC code | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2018-06-04 |
| Actual start date | 2018-06-04 |
| Estimated end date | 2018-07-06 |
| Actual end date | 2018-07-03 |
| Shortage status | Resolved |
| Updated date | 2018-07-04 |
| Company comments | limited quantity available |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 16750 ROUTE TRANSCANADIENNE KIRKLAND, QUEBEC CANADA H9H 4M7 |
| Company contact information | 1-800-567-2594 medinfocanada@merck.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v6 | 2018-07-04 | English | Compare |
| v5 | 2018-07-03 | French | Compare |
| v4 | 2018-07-03 | English | Compare |
| v3 | 2018-06-05 | English | Compare |
| v2 | 2018-06-04 | French | Compare |
| v1 | 2018-06-04 | English | Compare |
Showing 1 to 6 of 6